Opthea Limited Unsponsored ADR (NASDAQ:OPT) Given Consensus Recommendation of “Hold” by Analysts

Opthea Limited Unsponsored ADR (NASDAQ:OPT) has been given a consensus rating of “Hold” by the seven analysts that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $1.3333.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Opthea in a report on Monday.

Institutional Investors Weigh In On Opthea

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Twin Lakes Capital Management LLC raised its position in shares of Opthea by 67.4% in the first quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company’s stock valued at $113,000 after purchasing an additional 13,350 shares during the period. EP Wealth Advisors LLC purchased a new position in Opthea in the 1st quarter valued at approximately $34,000. OLD Mission Capital LLC raised its holdings in Opthea by 78.7% during the 1st quarter. OLD Mission Capital LLC now owns 19,167 shares of the company’s stock valued at $65,000 after acquiring an additional 8,439 shares during the period. Finally, Regal Partners Ltd lifted its position in shares of Opthea by 78.6% during the first quarter. Regal Partners Ltd now owns 5,193,688 shares of the company’s stock worth $17,710,000 after acquiring an additional 2,286,285 shares in the last quarter. 55.95% of the stock is currently owned by institutional investors.

Opthea Price Performance

The business’s 50-day moving average price is $3.41 and its 200-day moving average price is $3.41. Opthea has a 1-year low of $1.79 and a 1-year high of $6.30.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.